Tue, March 6, 2018
Mon, March 5, 2018
Fri, March 2, 2018
Thu, March 1, 2018
Wed, February 28, 2018
Tue, February 27, 2018
Mon, February 26, 2018
Fri, February 23, 2018
Thu, February 22, 2018
Wed, February 21, 2018
Tue, February 20, 2018
Fri, February 16, 2018
Thu, February 15, 2018

Matthew Harrison Maintained (BLUE) at Hold with Increased Target to $152 on, Feb 26th, 2018


//stocks-investing.news-articles.net/content/201 .. th-increased-target-to-152-on-feb-26th-2018.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "bluebird bio, Inc." (BLUE) at Hold with Increased Target from $151 to $152 on, Feb 26th, 2018.

Matthew has made no other calls on BLUE in the last 4 months.



There are 10 other peers that have a rating on BLUE. Out of the 10 peers that are also analyzing BLUE, 5 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Ying Huang of "B of A Securities" Maintained at Hold with Increased Target to $218 on, Thursday, February 22nd, 2018
  • Michael Schmidt of "Leerink Swann" Downgraded from Buy to Hold on, Thursday, January 25th, 2018
  • Mark Breidenbach of "Oppenheimer" Initiated at Hold on, Thursday, December 21st, 2017
  • Jason McCarthy of "Maxim Group" Downgraded from Strong Buy to Hold on, Wednesday, December 13th, 2017
  • Josh Schimmer of "Evercore ISI Group" Downgraded from Buy to Hold on, Monday, November 6th, 2017


These are the ratings of the 5 analyists that currently disagree with Matthew


  • Matthew Luchini of "BMO Capital" Maintained at Buy with Increased Target to $222 on, Thursday, February 22nd, 2018
  • Biren Amin of "Jefferies" Upgraded from Hold to Strong Buy on, Monday, December 11th, 2017
  • John Newman of "Canaccord Genuity" Initiated at Strong Buy and Held Target at $202 on, Tuesday, December 5th, 2017
  • Dane Leone of "BTIG" Upgraded from Hold to Strong Buy on, Thursday, November 2nd, 2017
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $162 on, Thursday, November 2nd, 2017

Publication Contributing Sources